| Literature DB >> 12615426 |
Jay S Dela Cruz1, Suk Ying Lau, Ernesto M Ramirez, Carla De Giovanni, Guido Forni, Sherie L Morrison, Manuel L Penichet.
Abstract
Previously protein vaccines consisting of the extracellular domain of HER2/neu (ECD(HER2)) were shown to elicit an immune response that does not provide protection against transplantable tumors expressing HER2/neu. Here, we showed that when mice were vaccinated with a mixture of human ECD(HER2) and anti-human HER2/neu IL-12, IL-2 or GM-CSF fusion proteins, significant retardation of the growth of a syngeneic carcinoma expressing rat HER2/neu, and long-term survivors were observed. Immune sera inhibited the in vitro growth of SK-BR-3, a human breast cancer overexpressing HER2/neu. Transfer of immune sera into mice challenged with TUBO also led to partial inhibition of tumor growth. Splenocytes from mice vaccinated with ECD(HER2) plus IgG3-(GM-CSF) incubated with ECD(HER2) demonstrated significant proliferation and IFN-gamma secretion. Taken together these results suggest that vaccines including ECD(HER2) and Ab-cytokine fusion proteins may be used to elicit both humoral and cell-mediated responses against HER2/neu.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12615426 DOI: 10.1016/s0264-410x(02)00741-7
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641